|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer显示文摘AIM: To investigate the correlation between uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) gene polymorphisms and irinotecan-associated side effects and parameters of drug efficacy in patients with metastatic colorectal cancer (mCRC) receiving a low-dose weekly irinotecan chemotherapeutic regimen. METHODS: Genotypes were retrospectively evaluated by gene scan analysis on the ABI 310 sequencer of the TATAA box in the promoter region of the UGT1A1 gene in blood samples from 105 patients who had received 1st line irinotecan-based chemotherapy for mCRC. RESULTS: The distribution of the genotypes was as follows: wild type genotype (WT) (6/6 ) 39.0%, heterozygous genotype (6/7) 49.5%, and homozygous genotype (7/7) 9.5%. The overall response rate (OR) was similar between patients carrying the (6/7, 7/7) or the WT genotype (6/6) (44.3% vs 43.2%, P = 0.75). Neither time to progression [(TTP) 8.1 vs 8.2 mo, P = 0.97] nor overall survival [(OS) 21.2 vs 18.9 mo, P = 0.73] differed significantly in patients who carried the(6/6) when compared to the (6/7, 7/7) genotype. No significant differences in toxicity were observed: Grade 3 and 4 delayed diarrhoea [(6/7, 7/7) vs (6/6); 13.0% vs 6.2%, P =0.08], treatment delays [(6/7, 7/7) vs (6/6); 25.1% vs 19.3%, P = 0.24] or dose reductions [(6/7, 7/7) vs (6/6); 21.5% vs 27.2%, P = 0.07].CONCLUSION: This analysis demonstrates the non-significant influence of the UGT1A1 gene polymorphism on efficacy and rate of irinotecan-associated toxicity in mCRC patients receiving low-dose irinotecan based chemotherapy. | Christoph Schulz Volker Heinemann Andreas Schalhorn Nikolas Moosmann Thomas Zwingers Stefan Boeck Clemens Giessen Hans-Joachim Stemmler | 2009 | World Journal of Gastroenterology2009，15，40： | 31 |
| 2 | Importance of performance status for treatment outcome in advanced pancreatic cancer显示文摘Despite progress in the treatment of advanced and metastatic pancreatic cancer (PC), the outcome of this disease remains dismal for the majority of patients. Given the moderate efficacy of treatment, prognostic factors may help to guide treatment decisions. Several trials identified baseline performance status as an important prognostic factor for survival. Unfit patients with a Karnofsky performance status (KPS) below 70% only have a marginal benefit from chemotherapy with gemcitabine (Gem) and may often benefit more from optimal supportive care. Once, however, the decision is taken to apply chemotherapy, KPS may be used to select either mono- or combination chemotherapy. Patients with a good performance status (KPS = 90%-100%) may have a significant and clinically relevant survival benefit from combination chemotherapy. By contrast, patients with a poor performance status (KPS ≤ 80%) have no advantage from intensified therapy and should rather receive single-agent treatment. | Stefan Boeck Axel Hinke Ralf Wilkowski Volker Heinemann | 2007 | World Journal of Gastroenterology2007，13，2： | 14 |
| 3 | 苹果擦伤拉曼光谱无损检测虚拟系统研究显示文摘为检测苹果品质并依据擦伤进行分级,研发了一个基于拉曼光谱的实时无损自动检测分类虚拟仪器分级系统样机。采用一台Nicolet傅氏变换拉曼光谱仪进行苹果擦伤光谱检测。测试集和训练集的苹果光谱用WinDAS的典型变量分析(CVA)和主成分分析法(PCA)进行分类处理。分析得出的模型经UNEQ分类检验,'马氏平方图'和χ2检验结果该分类模型。其次,应用LabVIEW设计苹果虚拟仪器分级控制系统,并制作了样机。试验结果表明拉曼光谱分析能用于苹果擦伤无损检测和类别确定;虚拟仪器分级系统能对苹果进行准确分级处理。 | 高晓阳 Paul Heinemann Joseph Irudayaraj | 2005 | 农业工程学报2005，21，3： | 14 |
| 4 | FOLFIRI联合西妥昔单抗或贝伐珠单抗治疗晚期结直肠癌:随机临床试验FIRE-3的最终生存及符合方案分析显示文摘背景:在FIRE-3研究中,与贝伐珠单抗+FOLFIRI相比,西妥昔单抗+FOLFIRI可提高KRAS野生型转移性结直肠癌(mCRC)的总生存率,但是未发现相应的无进展生存获益。本研究目的在于分析RAS野生型结直肠癌接受一线FOLFIRI治疗的可评价疗效患者中,与贝伐珠单抗相比,西妥昔单抗是否可改善治疗反应和生存情况,同时分析原发肿瘤部位对预后的影响。方法:意向治疗人群包括593例KRAS第2外显子野生型mCRC患者。进一步检测确认400名患者为全RAS野生型肠癌,其中352名(88%)患者接受了至少3个周期的治疗和至少1次基线后的影像检查以评估疗效,并纳入符合方案的患者(西妥昔单抗组169名,贝伐珠单抗组183名)。 | 何婉 HEINEMANN V VON WEIKERSTHAL L F DECKER T | 2021 | 结直肠肛门外科2021，27，1： | 11 |
| 5 | 基于LabVIEW的苹果擦伤分级系统设计显示文摘基于美国USDA苹果分级标准研制了苹果擦伤检测分级系统样机。系统依据所研究的苹果表面擦伤拉曼光谱PLS/CVA处理和UNEQ模型分类,通过设计的LabVIEW虚拟仪器控制系统实时完成苹果分级。对48个预先分级的美国红元帅苹果(reddelicious#4167)分别进行两轮实际分级实验来评估该系统的性能。实验结果表明该分级检测系统对无擦伤、轻擦伤和重擦伤苹果组的分级平均准确率分别为100%、99%、97%。分级系统每分钟可分级苹果3~6个,对运动苹果分级误判率较低,是实施苹果自动检测分级生产线的基本模块。 | 高晓阳 Paul H Heinemann Joseph Irudayaraj | 2006 | 农业机械学报2006，37，4： | 9 |
| 6 | Potential triggering factors of acute liver failure as a first manifestation of autoimmune hepatitis-a single center experience of 52 adult patients显示文摘AIM To investigate potential triggering factors leading to acute liver failure(ALF) as the initial presentation of autoimmune hepatitis(AIH).METHODS A total of 565 patients treated at our Department between 2005 and 2017 for histologically-proven AIH were retrospectively analyzed. However, 52 patients(9.2%) fulfilled the criteria for ALF defined by the 'American Association for the Study of the Liver(AASLD)'. According to this definition, patients with 'acute-on-chronic' or 'acute-on-cirrhosis' liver failure were excluded. Following parameters with focus on potential triggering factors were evaluated: Patients' demographics, causation of liver failure, laboratory data(liver enzymes, MELD-score, autoimmune markers, virus serology), liver histology, immunosuppressive regime, and finally, outcome of our patients.RESULTS The majority of patients with ALF were female(84.6%) and mean age was 43.6 ± 14.9 years. Interestingly, none of the patients with ALF was positive for antiliver kidney microsomal antibody(LKM). We could identify potential triggering factors in 26/52(50.0%) of previously healthy patients presenting ALF as their first manifestation of AIH. These were drug-induced ALF(57.7%), virus-induced ALF(30.8%), and preceding surgery in general anesthesia(11.5%), respectively. Unfortunately, 6 out of 52 patients(11.5%) did not survive ALF and 3 patients(5.7%) underwent liver transplantation(LT). Comparing data of survivors and patients with non-recovery following treatment, MELDscore(P < 0.001), age(P < 0.05), creatinine(P < 0.01), and finally, ALT-values(P < 0.05) reached statistical significance. CONCLUSION Drugs, viral infections, and previous surgery may trigger ALF as the initial presentation of AIH. Advanced age and high MELD-score were associated with lethal outcome. | Matthias Buechter Paul Manka Falko Markus Heinemann Monika Lindemann Hideo Andreas Baba Martin Schlattjan Ali Canbay Guido Gerken Alisan Kahraman | 2018 | World Journal of Gastroenterology2018，24，13： | 8 |
| 7 | Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy显示文摘 | Michael Haas Volker Heinemann Frank Kullmann Rüdiger P. Laubender Christina Klose Christiane J. Bruns Stefan Holdenrieder Dominik P. Modest Christoph Schulz Stefan Boeck | 2013 | Journal of Cancer Research and Clinical Oncology2013，，4： | 4 |
| 8 | Systemic treatment of advanced pancreatic cancer显示文摘 | Volker Heinemann Michael Haas Stefan Boeck | 2011 | Cancer Treatment Reviews2011，，7： | 3 |
| 9 | Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR显示文摘 | Volker Heinemann Sebastian Stintzing Thomas Kirchner Stefan Boeck Andreas Jung | 2008 | Cancer Treatment Reviews2008，，3： | 3 |
| 10 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study显示文摘 | J.A. Ajani M. Buyse M. Lichinitser V. Gorbunova G. Bodoky J.Y. Douillard S. Cascinu V. Heinemann R. Zaucha A. Carrato D. Ferry V. Moiseyenko | 2013 | European Journal of Cancer2013，，： | 3 |
| 11 | 钢铁厂高能效利用副产煤气的可行途径显示文摘钢铁厂在生产过程中,副产了大量可燃煤气。副产煤气热值范围在3~20MJ/Nm3,所含的热量可被利用,如:电厂、焦炉、热风炉、热轧厂等所需燃料,可用副产煤气部分替代天然气,减少煤气放散,降低公司的能耗成本和环境污染。使用副产煤气虽能得益却也面临难题。副产煤气的产量和成分取决于生产和工艺状况,煤气用户必须随之调整其操作。用气设备的启停操作改变了煤气用量,造成煤气管网压力波动,副产煤气成分变化则会引起热值波动,一旦管网压力波动或成分改变,将对管网上用气单元的燃烧过程产生不利影响。针对副产煤气利用的复杂情况,AMB、AMEH和BFI公司开发了高能效利用副产煤气的途径,应用于部分钢铁厂,如:改善煤气管网压力和流量分布的技术,具备供需分布显示和预报功能的煤气管理系统。介绍了煤气管网压力波动控制以及副产煤气利用的结果和经验。 | Bernhart Stranzinger Frank Hohlweg Olaf Heinemann 李晓清 | 2012 | 世界钢铁2012，12，5： | 3 |
| 12 | KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer显示文摘 | Stefan Boeck Andreas Jung Rüdiger P. Laubender Jens Neumann Rosalind Egg Clara Goritschan Steffen Ormanns Michael Haas Dominik P. Modest Thomas Kirchner Volker Heinemann | 2013 | Journal of Gastroenterology2013，，4： | 2 |
| 13 | Growth of Chlamydia pneumoniae induces cytokine production and expression of CD14 in a human monocytic cell line显示文摘 | Heinemann M Susa M Simnacher U | 1996 | Infect Immun1996，64，11： | 2 |
| 14 | FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial显示文摘 | Volker Heinemann Ludwig Fischer von Weikersthal Thomas Decker Alexander Kiani Ursula Vehling-Kaiser Salah-Eddin Al-Batran Tobias Heintges Christian Lerchenmüller Christoph Kahl Gernot Seipelt Frank Kullmann Martina Stauch Werner Scheithauer J?rg Hielscher | 2014 | Lancet Oncology2014，，10： | 2 |
| 15 | Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action显示文摘 | V. Heinemann J.Y. Douillard M. Ducreux M. Peeters | 2013 | Cancer Treatment Reviews2013，，6： | 2 |
| 16 | Detection of contaminants in cell cultures, sera and trypsin显示文摘 | Tatiana Flávia Pinheiro de Oliveira Ant?nio Augusto Fonseca Marcelo Fernandes Camargos Anapolino Macedo de Oliveira Ana Cláudia Pinto Cottorello Antonizete dos Reis Souza Iassudara Garcia de Almeida Marcos Bryan Heinemann | 2013 | Biologicals2013，，6： | 2 |
| 17 | Incidince and impact of systemic venous collateral development after Glenn and Fontan procedures显示文摘 | Heinemann M Breuer J Steger V | 2001 | Thorac Cardiovasc Surg2001，49，3： | 2 |
| 18 | Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial显示文摘 | Dominik P. Modest Ruediger P. Laubender Sebastian Stintzing Clemens Giessen Christoph Schulz Michael Haas Ulrich Mansmann Volker Heinemann | 2013 | Acta Oncologica2013，，5： | 2 |
| 19 | The menopause ration scale(MRS) as outcome measure for hormone treatment? A validation study显示文摘 | HEINEMANN L A J DOMINH T STRELOW F | 2004 | Health and Quality of Life Outcomes2004，2，： | 1 |
| 20 | Relationship between pore size and the gas pressure dependence of the gaseous thermal conductivity显示文摘 | REICHENAUER G HEINEMANN U EBERT H P | 2007 | Colloids and Surfaces A:Physicochem2007，，300： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员